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Background: Head and neck squamous cell carcinoma (HNSCC) mortality rates have not shown significant reduction
in decades. Platelets are being implicated in having cancer-promoting roles, an observation supported by the adverse
outcomes associated with thrombocytosis in many malignancies associated with thrombocytosis. However, the
prognostic significance of platelet counts in HNSCC is unknown. Here, we comprehensively investigate the predictive
value of platelet counts at diagnosis and post-diagnosis antiplatelet treatment in the overall survival of HNSCC patients.
Methods: The study population consists of 1051 pathologically confirmed HNSCC cases diagnosed between years
2000 and 2012 in a tertiary medical center. Platelet count was investigated as a predictor of survival by fitting
Cox Proportional Hazards (CPH) regression models to generate Hazard Ratios (HR) and 95% confidence intervals
(CI), while adjusting for age, sex, race, stage, treatment and smoking status. Finally, we evaluated the association
between overall survival and antiplatelet medication intake after diagnosis.
Results: Multivariable analysis showed an increased death rate in patients with thromobocytosis [HR 2.37, 95% CI
1.60-3.50)] and high normal platelet counts [HR 2.20, 95% CI 1.58-3.05] compared to the reference middle normal
group. Post-diagnosis treatment with antiplatelet medications was inversely associated with death rate [HR 0.76,
95% CI 0.58-0.99].
Conclusions: Higher platelet counts were associated with poorer prognosis in HNSCC patients, whereas antiplatelet
agents were associated with better prognosis. Antiplatelet agents warrant evaluation in preclinical and clinical
settings as a way to improve survival in HNSCC.Introduction
Head and neck cancer is common in many areas across
the world and is mainly linked to tobacco smoking, alco-
hol consumption and Human Papilloma Virus (HPV) in-
fections. Fifty-five thousand cases are newly diagnosed
each year in the United States [1] and 550,000 world-
wide [2]. Recent work has shown hematological parame-
ters including neutrophils, lymphocytes and monocytes
to predict outcome in head and neck cancers [3-5]. In* Correspondence: zihai@musc.edu
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unless otherwise stated.addition, pretreatment thrombocytosis correlated with
shorter survival in oral squamous cell carcinoma [6]. In-
triguingly, thrombocytosis, which is highly prevalent in
cancer patients [7], is a poor prognostic indicator in a
number of cancers [8-13].
The relation between platelets and cancer progression sug-
gests a possible role that extends beyond their hemostatic
function [14,15]. More recently, platelets have been
recognized as mediators of other regulatory functions
in physiology such as angiogenesis, wound healing and
immunomodulation [15]. Platelets secrete cytokines and
growth factors such as TGF-β [16], VEGF [17], MMP-2,
PF4 [18] and PDGF [19], which in turn induce hallmarks
of cancer progression such as epithelial-mesenchymal
transition (EMT) [20], angiogenesis, cell migration and/orLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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of PDGFR and EGFR, resulting in EGFR transactivation
[21]. Platelet-derived TGF-β also acts on cancer cells to
activate the Smad and NF-κB pathways, thus promoting
cancer metastasis [22]. As a perpetuating mechanism, can-
cer cells can also produce soluble mediators such as IL-6
and GM-CSF, which stimulate thrombopoiesis [23,24].
Interestingly, the use of drugs with antiplatelet activity,
such as aspirin, is associated with lower incidence and bet-
ter prognosis in colon cancer and other cancers [25,26].
In the present investigation, we examine closely and sys-
temically the relationship between platelet count in the
peripheral venous blood and survival in head and neck
squamous cell cancer (HNSCC), including oral, pharyngeal
and laryngeal cancers. In particular, we investigate the
prognostic significance of platelet counts within the nor-
mal and abnormal ranges to determine if there is a linear
association between platelet number and clinical outcome.
To further investigate the role of platelets in HNSCC, we
studied the association of medications known to interfere
with platelet function; anti-platelet medications and non-
steroidal anti-inflammatory drugs (NSAIDs) [27], with sur-
vival of HNSCC patients.
Subjects and methods
Patient inclusion and exclusion criteria
The Cancer Registry at Hollings Cancer Center, Medical
University of South Carolina (MUSC) was used to iden-
tify all cases of HNSCC (squamous cell cancers of the
oral cavity, pharynx and larynx). The study population
was comprised of histologically confirmed cases diag-
nosed between January 1, 2000 and June 30, 2012. After
excluding patients diagnosed with a second primary can-
cer between January 1, 1993 (the earliest date recorded)
and June 30, 2013, there were 1376 HNSCC patients avail-
able for the study. Patients without recorded platelet counts
were also excluded, resulting in a total of 1051 patients
available for analysis. The follow-up period ranged between
2 weeks and 156 months, with a median 25.7 months.
Data collection
The MUSC Institutional Review Board approved all study
activities. For each case, we abstracted data on demo-
graphic characteristics, clinical and pathological variables
at diagnosis, treatment received and outcome using two
different data sources: the Hollings Cancer Center (HCC)
cancer registry and the MUSC Clinical Data Warehouse
(CDW). The registry is part of a state mandated data sys-
tem that collects cancer incidence on all cases in South
Carolina. The CDW is a single, secure and integrated
database extracted from the MUSC OACIS Clinical Data
Repository, which includes patient demographics, ICD-
coded diagnoses, ICD-coded procedures, medications and
laboratory test results. These databases were subsequentlylinked, in a blinded fashion, through an honest broker at
the CDW, and entered into a secured study database.
Independent variables obtained from the CDW included
socio-demographic characteristics (age at diagnosis, sex and
race); pre-treatment platelet count, lifestyle factors includ-
ing smoking status (never, former and current) and alcohol
use (never, former and current); and use of platelet-
interfering medications, namely NSAIDs or antiplatelet
medications, after diagnosis. NSAIDs included aspirin, cel-
ecoxib, rofecoxib, valdecoxib, diclofenac, etodolac, ibu-
profen, indomethacin, ketorolac, meloxicam, nabumetone,
naproxen, oxaprozin, sulindac and choline magnesium tri-
salicylate. Antiplatelet medications included cilostazol,
clopidogrel, prasugrel, ticlopidine, abciximab, eptifibatide,
tirofiban, anagrelide, dipyridamole, dipyridamole and as-
pirin. Intake of medications was based on the inpatient
records of the CDW. Tumor-related variables obtained
from the registry included tumor grade (well differenti-
ated, moderately differentiated, poorly differentiated/
undifferentiated); location of the primary tumor (oral
cavity, pharynx, larynx); TNM stage (I, II, III, IV); and re-
ceipt of all first-line therapies (chemotherapy, surgery,
radiation and/or other). Because there were only 5
cases with undifferentiated grade, we combined these
with poorly differentiated grade into a single category
for the purposes of analysis.
Data analysis
The main study outcome was overall survival. Survival
time was calculated as the time from diagnosis with
HNSCC to death from any cause through July 19, 2013.
Subjects alive as of this date were censored at the end of
follow-up. Kaplan-Meier methods were used to generate
median survival time and corresponding 95% confidence
intervals for five classes of platelet count (low, low-normal,
mid-normal, high-normal and high). Abnormal platelet
count was defined as thrombocytopenia (“low”, <150,000/
μL) or thrombocytosis (“high”, ≥400,000/μL). Within the
normal range (150–399), we a priori sub-divided pa-
tients into approximate thirds [i.e. low-normal (150–229),
mid-normal (230–314) and high-normal (315–399)].
Kaplan-Meier curves were plotted to graphically assess
the relationship between the five categories of platelets
(described above) and survival. The log-rank test was used
to assess statistical significance.
We evaluated the association between the 5 platelet cat-
egories and survival by fitting univariate Cox Proportional
Hazards (CPH) regression models. We also analyzed plate-
lets as a continuous variable within the normal range. We
chose to restrict the analysis to the normal range because
the relationship between platelets and death was non-
linear (u-shaped curve) in the lower tail of the distribution.
To control for potential confounding variables, we per-
formed univariate CPH for all other variables in Table 1
Table 1 Demographic and clinical characteristics within the five categories of platelet counts
Platelet count categories
Variable Low (1–149)N = 67
Low normal
(150–229) N = 361
Mid normal
(230–314) N = 379
High normal
(315–399) N = 169
High (≥400)
N = 75 p-value
Age—yrs. Mean (SD) 60.0 (10.7) 61.0 (10.8) 58.4 (11.9) 58.0 (10.8) 58.2 (11.5) 0.009
Male—no. (%) 55 (82) 302 (84) 273 (72) 117 (69) 53 (71) <0.0001
Race—no. (%) <0.0001
Caucasian 48 (72) 287 (79) 293 (77) 116 (69) 42 (56)
African American 18 (27) 67 (19) 83 (22) 52 (31) 33 (44)
Other 1 (1.5) 7 (2) 3 (1) 1 (0.5) 0 (0)
Smoker—no. (%) <0.0001
Never 6 (9) 63 (19) 67 (19) 18 (11) 4 (6)
Former 20 (32) 125 (38) 111 (32) 40 (25) 14 (20)
Current 37 (59) 145 (43) 173 (50) 102 (64) 52 (74)
Alcohol – no. (%) 0.02
Never 17 (27) 99 (30) 108 (29) 36 (23) 7 (10)
Former 13 (20) 55 (17) 54 (14) 26 (17) 9 (14)
Current 34 (53) 174 (53) 177 (46) 94 (60) 50 (76)
Stage 0.034
I 6 (11) 42 (15) 42 (14) 8 (7) 5 (8)
II 9 (17) 37 (13) 35 (12) 10 (8) 4 (6)
III 9 (17) 60 (21) 50 (17) 18 (15) 9 (14)
IV 29 (55) 147 (51) 168 (57) 87 (71) 47 (72)
Grade 0.90
Undetermined 20 (30) 106 (29) 103 (27) 42 (25) 16 (21)
I. Well Differentiated 9 (13) 43 (12) 49 (13) 18 (11) 8 (11)
II. Moderately 29 (43) 152 (42) 164 (43) 80 (47) 41 (55)
III. Poorly or undifferentiated 9 (13) 59 (17) 63 (17) 29 (17) 10 (13)
Primary Site 0.09
Oral 34 (51) 171 (47) 190 (50) 100 (59) 34 (45)
Pharynx 13 (19) 101 (28) 107 (28) 42 (25) 18 (24)
Larynx 20 (30) 89 (25) 82 (22) 27 (16) 23 (31)
Post-diagnosis NSAIDs and/or Anti-platelets 0.33
No no. (%) 48 (72) 259 (72) 277 (73) 133 (79) 60 (80)
Yes no. (%) 19 (28) 102 (28) 102 (27) 36 (21) 15 (20)
All variables had complete data (n = 1051) except: smoking status (n = 977), alcohol use (n = 953), clinical stage (n = 822) and tumor grade, where the
undetermined category accounted for n = 247 cases.
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tumor grade, location and clinical stage). Multivariable
CPH models were then fit for the platelet variable and all
other variables that were found to have a p-value of < 0.20
in the univariate analysis. Variables were retained in the
final CPR model if they were significant at p < 0.05.
Additionally, for each model, we examined two-way in-
teractions between platelet measures and variables that
were significant in the multivariable model. Interactions
were retained in the final model if they were significant
at p < 0.05.The methodology described above was used to exam-
ine the relationship between post-diagnosis use of NSAIDs/
antiplatelets and survival. The association between any
post-diagnosis NSAIDs/antiplatelet medication use (Yes
or No) and survival was assessed while adjusting for
age, race, smoking, treatment, tumor site, tumor grade,
platelet level (continuous, or platelet classes) and clinical
stage. We also examined the association of medication use
and survival while excluding those with pre-diagnostic
thrombocytopenia (who would not be expected to benefit
from antiplatelet medications). The interaction between
Table 2 Relative hazard of death in HNSCC patients based on platelet counts
Variables Low (<150) N = 67 Low normal(150–229) N = 361
Mid-normal
(230–314) N = 379
High normal
(315–399) N = 169 HIGH (≥400) N = 75
Number dead (%) 37 (55) 150 (42) 146 (39) 105 (62) 53 (71)
Median Survival Months (95% CI) 37.7 (20.7- 84.8) 64.0 (53.6-78.9) 74.7 (60.7 100.4) 23.8 (17.7 - 36.7) 16.3 (11.8 -29.2)
p-value for difference <0.0001
Overall Survival
Unadjusted HR (95% CI) 1.52 (1.06-2.18) 1.07 (0.85-1.34) 1.0 (reference) 1.98 (1.54-2.55) 2.64 (1.92 -3.61)
Adjusted HR (95% CI) 1.50 (0.96-2.35) 1.25 (0.93-1.68) 1.0 (reference) 2.20 (1.58-3.05) 2.37 (1.60-3.50)
HR (95% CI) by Stage
I (n = 103) 0.41 (0.05-.3.31) 1.18 (0.33-4.20) 1.0 (reference) 1.60 (0.27-9.54) 0.35 (0.03-4.18)
II (n = 95) 1.99 (0.52-7.67) 1.40 (0.57-3.38) 1.0 (reference) 1.54 (0.48-4.99) 1.83 (0.45-7.40)
III (n = 146) 0.74 (0.16-3.40) 1.32 (0.62-2.82) 1.0 (reference) 2.43 (0.91-6.50) 1.86 (0.53-6.45)
IV (n = 478) 2.33 (1.34-4.10) 1.18 (0.78-1.78) 1.0 (reference) 2.50 (1.66-3.76) 2.47 (1.55-2.93)
Adjusted model controls for age, race, site, grade, treatment, smoking and stage.
P for interaction between stage and classes of platelets p = 0.31.
Figure 1 High normal platelets and thrombocytosis are
associated with worse overall survival. (log-rank p < 0.0001).
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sification survival was also evaluated.
Results
Relationship between platelet counts and clinical
characteristics in HNSCC
Age inversely correlated with platelet counts, where pa-
tients in the low normal and low categories were slightly
older than those in the other groups (Table 1). The ma-
jority of patients were males, but females were enriched
in the higher platelet groups (mid-normal, high normal
and high) (Table 1). In addition, African American pa-
tients were more represented in the thrombocytosis
group where they comprised more than half of that
population. Current smoking and alcohol consumption
in turn were significantly associated with higher platelet
counts (Table 1). Intriguingly, compared to those with
stage I-III disease, higher platelet counts were observed in
stage IV HNSCC (Table 1), although platelet levels did
not significantly correlate with tumor grade or ana-
tomic site (Table 1). No significant association was ob-
served between intake of antiplatelet medications/NSAIDs
and the platelet count. Finally, the proportion of deceased
patients was higher in the high normal and thrombocyto-
sis groups.
Higher platelet counts are associated with worse overall
survival
Compared to those in the mid-normal category, pa-
tients in the high normal (adjusted HR 2.20; 95% CI
1.58-3.05) and thrombocytosis (adjusted HR 2.37; 95%
CI 1.60-3.50) groups had more than two times higher
death rates (Table 2 and Figure 1). The results for pa-
tients with platelet counts below the mid-normal cat-
egory also trended toward poorer survival with adjustedhazard ratios of 1.25 (95% CI 0.93-1.68) in the low
normal and 1.50 (95% CI 0.96-2.35) in the low cat-
egories, although these differences were not statisti-
cally significant.
Strikingly, when platelet count was modeled as a con-
tinuous variable within the normal range, an increase of
platelets by 100,000/μL resulted in a 32% increase in the
hazard ratio (p = 0.001) in the unadjusted model. The in-
crease in hazard was 30% (p = 0.01) after controlling for
age, race, treatment, tumor site, tumor grade, smoking
and stage.
The univariate association between platelet count and
risk of death was assessed for three tumor sites (oral,
pharynx, and larynx). Patients with thrombocytosis com-
pared to those in the mid-normal range had a HR of 4.35
(95% CI 2.75-6.87) for oral cancer, 2.41 (95% CI 1.32-4.44)
for pharyngeal cancer, and 1.48 (95% 0.78-2.80) for laryn-
geal cancer.
Table 3 Association of antiplatelet medications and risk
of death
HR 95% CI p-value
Antiplatelet No Yes
Unadjusted 1.0 0.73 (0.58-0.92) 0.0008
Adjusted* 1.0 0.76 (0.58-0.99) 0.04
Antiplatelet medications in 5 categories of platelet counts
Low 1.0 1.74 (0.74-4.09) 0.20
Low Normal 1.0 0.88 (0.55-1.42) 0.58
Mid Normal 1.0 0.68 (0.42-1.11) 0.12
High normal 1.0 0.87(0.48-1.51) 0.64
High 1.0 0.42 (0.17-1.05) 0.06
*Adjusted for age, race, tumor site, grade, treatment, platelet count
and smoking.
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overall survival
Patients who were prescribed antiplatelet medications or
NSAIDs after the date of diagnosis had a reduced risk of
death compared to the other patients [HR 0.76, 95% CI
0.58- 0.99] after controlling for age, race, stage, grade,
tumor site, treatment, smoking status, and platelet count
(continuous) (Table 3 and Figure 2). The HR for medica-
tion use and death rate was 0.80 (95% CI 0.61-1.05)
when we adjusted for age, race, stage, grade, tumor site,
treatment, smoking status, and platelet classification.
The association between the use of antiplatelet medica-
tions and death was stronger, however, when patients
with thrombocytopenia were excluded: HR 0.73 (95 CI
0.55-0.98; p = 0.04). The association between medication
intake and survival was assessed within each of the five
platelet categories. Within the normal platelet range, in-
take of NSAIDs/antiplatelet conferred variable HRs in
the protective direction, none of which was statistically
significant. However, the protective association with intake
of antiplatelet medications was strongest in the thrombo-
cytosis group compared to those not taking medications
[HR 0.42, 95% CI 0.17-1.05), p = 0.06] (Table 3).Figure 2 Antiplatelets/NSAIDs are inversely associated with survival i
the general HNSCC patient population, B. The benefit associated with intak
group, HR = 0.42, p = 0.06. AP: Antiplatelets. ns: Not significant.Discussion
The present study observed a clear association between
higher platelet counts and worse overall survival in HNSCC.
The results suggested that higher platelet levels, even in
the normal range, are associated with poorer survival.
The evidence that the observed association between
platelets and overall survival is genuine was solidified by
the observation that the post-diagnostic intake of medi-
cations known to interfere with platelet function was as-
sociated with reduced risk of death in HNSCC patients,
particularly among those with thrombocytosis. The fact
that pharmacologic interventions aimed at lowering plate-
lets were associated with prolonged survival provides
quasi-experimental evidence that platelets are indeed
linked with poor prognosis, reducing the likelihood that
the observed association was due to bias or confounding
factors. However, this evidence would be even stronger if
it was clear that the observed association was due to an
anti-platelet effect of these medications, but at the present
time it cannot be ruled out that this association is attribut-
able to the anti-inflammatory effects of many anti-platelet
medications. However, given the recognized role of plate-
lets in promoting cancer metastasis in preclinical animal
models [22], it is likely that antiplatelet agents confer a
beneficial effect and improve overall survival in cancer
patients.
A limitation of our study is that we were unable to ac-
count for the amount and duration of intake of these
agents, nor the start of their intake after diagnosis. The
measurement error introduced likely resulted in bias to-
ward the null hypothesis, but future studies with more
detailed measurement of the anti-platelet medications
are needed to refine our understanding on this issue.
Of note, our results suggested that low platelet counts
(<150,000/μL) were associated with a trend towards
worse overall survival compared to those in the low nor-
mal and mid-normal groups. However, the difference be-
tween the two groups did not reach statistical significance
and is thus inconclusive. Alternatively, even if the nulln HNSCC. A. Intake of these medications confers better outcomes in
e of antiplatelets/NSAIDs is particularly observed in the thrombocytosis
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sample size, the possible explanations include patho-
logical thrombocytopenia acting as a marker of poor
hematological function associated with advanced disease.
This consideration emphasizes the importance of consid-
ering a potential U-shaped relationship between platelet
counts and cancer survival in future research on this
topic.
Conclusions
In conclusion, higher platelet counts were strongly associ-
ated with worse overall survival in a large cohort of head
and neck cancer patients, whereas anti-platelet medica-
tions were associated with better survival. These findings,
if replicated, have direct translational implications. Given
the worse prognosis associated with higher platelet
counts, and the potentially protective effect of platelet in-
hibitors in counteracting the effect of platelets, the investi-
gation of anti-platelet agents in the treatment of HNSCC
is warranted, especially that such agents are widely avail-
able and approved for other indications.
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